Cartesian Therapeutics Inc

詳細情報 Cartesian Therapeutics Inc 企業名

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

企業情報

企業コードRNAC

会社名Cartesian Therapeutics Inc

上場日Jun 22, 2016

最高経営責任者「CEO」Dr. Carsten Brunn, Ph.D.

従業員数66

証券種類Ordinary Share

決算期末Jun 22

本社所在地7495 New Horizon Way

都市FREDERICK

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号21703

電話番号13013488698

ウェブサイトhttps://www.cartesiantherapeutics.com/

企業コードRNAC

上場日Jun 22, 2016

最高経営責任者「CEO」Dr. Carsten Brunn, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Murat Kalayoglu, M.D., Ph.D.

Independent Director

502.42K

-1.74%

Dr. Emily English, Ph.D.

Chief Operations Officer

36.95K

+25.46%

Dr. Carsten Brunn, Ph.D.

President, Chief Executive Officer, Director

30.24K

-38.23%

Dr. Milos Miljkovic, M.D.

Chief Medical Officer

17.12K

--

Mr. Blaine Davis

Chief Financial Officer

12.21K

-87.12%

Mr. Patrick J. (Pat) Zenner

Independent Director

3.82K

-14.03%

Dr. Kemal Malik

Independent Director

--

-100.00%

Dr. Michael S. Singer, M.D., Ph.D.

Independent Director

--

Mr. Timothy C. (Tim) Barabe

Independent Director

--

Dr. Nishan M. de Silva, M.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Murat Kalayoglu, M.D., Ph.D.

Independent Director

502.42K

-1.74%

Dr. Emily English, Ph.D.

Chief Operations Officer

36.95K

+25.46%

Dr. Carsten Brunn, Ph.D.

President, Chief Executive Officer, Director

30.24K

-38.23%

Dr. Milos Miljkovic, M.D.

Chief Medical Officer

17.12K

--

Mr. Blaine Davis

Chief Financial Officer

12.21K

-87.12%

Mr. Patrick J. (Pat) Zenner

Independent Director

3.82K

-14.03%

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Thu, Aug 14

株主統計

種類

株主統計

比率

Springer Timothy A

33.22%

Seven One Eight Three Four Irrevocable Trust

17.52%

Fidelity Management & Research Company LLC

8.98%

Singer (Michael S.)

2.72%

MPM BioImpact LLC

2.64%

他の

34.93%

株主統計

比率

Springer Timothy A

33.22%

Seven One Eight Three Four Irrevocable Trust

17.52%

Fidelity Management & Research Company LLC

8.98%

Singer (Michael S.)

2.72%

MPM BioImpact LLC

2.64%

他の

34.93%

種類

株主統計

比率

Individual Investor

39.87%

Corporation

20.04%

Investment Advisor

17.88%

Investment Advisor/Hedge Fund

5.50%

Hedge Fund

1.66%

Research Firm

0.24%

Insurance Company

0.08%

Bank and Trust

0.05%

Pension Fund

0.03%

他の

14.64%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

206

22.27M

85.81%

-1.28M

2025Q1

226

22.94M

90.08%

+138.68K

2024Q4

230

22.26M

88.90%

-105.22K

2024Q3

229

20.22M

92.77%

+6.58M

2024Q2

235

14.41M

85.20%

+9.02M

2024Q1

233

3.74M

346.71%

-1.42M

2023Q4

240

3.82M

71.00%

-922.87K

2023Q3

251

3.63M

70.60%

-1.17M

2023Q2

261

3.72M

72.70%

-649.68K

2023Q1

272

3.43M

67.38%

-196.84K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Springer Timothy A

8.64M

33.28%

+22.36K

+0.26%

Apr 14, 2025

Seven One Eight Three Four Irrevocable Trust

4.56M

17.55%

--

Apr 14, 2025

Fidelity Management & Research Company LLC

2.34M

9.02%

-83.30K

-3.44%

Mar 31, 2025

Singer (Michael S.)

707.06K

2.72%

-623.00

-0.09%

Apr 14, 2025

MPM BioImpact LLC

790.78K

3.05%

+69.64K

+9.66%

Mar 31, 2025

TAS Partners, L.L.C.

656.51K

2.53%

+126.72K

+23.92%

Apr 14, 2025

BlackRock Institutional Trust Company, N.A.

608.03K

2.34%

+1.49K

+0.25%

Mar 31, 2025

Invus Public Equities Advisors, LLC

563.27K

2.17%

-8.96K

-1.57%

Mar 31, 2025

Kalayoglu (Murat)

502.42K

1.94%

-8.88K

-1.74%

Apr 14, 2025

The Vanguard Group, Inc.

503.54K

1.94%

+74.06K

+17.24%

Mar 31, 2025

詳細を見る

10.310USD

Cartesian Therapeutics Inc

10.310

概要

企業名

金融

分析